
    
      Eligibility Female adults(18-70 years old) are eligible if they had histologically confirmed
      primary breast cancer. Patients also had Eastern Cooperative Oncology Group(ECOG) Performance
      status of 0 or 1, absolute neutrophil count (ANC)>1500/mm3,hemoglobin >90g/dL, and platelet
      count >100,000/mm3,creatinine<2.5 times the upper limit of normal(ULN)）, transaminases<3
      times ULN or alkaline phosphatase<4 times ULN if transaminases was normal, and total
      bilirubin <1.5 times ULN. Exclusion criteria were active infection, pregnancy, other primary
      malignancy (except in situ carcinoma of cervix or adequately treated nonmelanomatous
      carcinoma of the skin), any documented distant metastasis and uncontrolled systemic diseases.

      This study protocol was approved by institutional ethic review boards and conducted according
      to guidelines for good clinical practice and the Helsinki Declaration.All patients provided
      written informed consent.

      Outcome Measures Primary Endpoint：5 year Disease Free Survival（DFS） Second Endpoints：5 year
      distant disease free survival （DDFS） 5 year event free survival （EFS） 5 year overall survival
      （OS） 5 year DFS in gBRCA1 mutation carriers and homologous recombination repair (HRR)-related
      gene mutation carriers
    
  